1. Home
  2. Stock quotes
  3. Lexaria Bioscience Corp.
  4. Financial Statements
  5. Income Statement
Lexaria Bioscience Corp. logo
Lexaria Bioscience Corp. LEXX
$ 0.9 -32.84%

Quarterly report 2025-Q2
added 07-14-2025

report update icon

Lexaria Bioscience Corp. Income Statement 2011-2025 | LEXX

Annual Income Statement Lexaria Bioscience Corp.

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

 33.5 M 10.1 M 7.44 M 17.6 M - - - - - - - - - -

Shares

 15.8 M 8.09 M 5.95 M 4.39 M - - - - - - - - - -

Historical Prices

 2.12 1.25 1.25 4.03 - - - - - - - - - -

Net Income

 -5.8 M -6.66 M -7.27 M -4.19 M - - - - - - - - - -

Revenue

 464 K 226 K 255 K 723 K - - - - - - - - - -

Cost of Revenue

 4.82 K 31.5 K 71.8 K 175 K 99.4 K 22.9 K 25.2 K 29.8 K 45.6 K - - 795 K 783 K 668 K

Gross Profit

 459 K 195 K 184 K 547 K - - - - - - - - - -

Operating Income

 -5.75 M -6.53 M -6.62 M - - - - - -1.28 M -1.98 M -1.56 M - - -

Interest Expense

 -55.5 K -179 K -765 K - - - - 6.02 K 2.25 K 31.5 K 166 K 267 K 238 K 224 K

EBITDA

 -5.68 M -6.39 M -6.52 M 112 K - - - - - - - - - -

Operating Expenses

 6.21 M 6.73 M 6.8 M 6.23 M - - - - - - - - - -

General and Administrative Expenses

 3.85 M 3.06 M 4.96 M 4.97 M - - - - - - - - - -

All numbers in USD currency

Quarterly Income Statement Lexaria Bioscience Corp.

2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

 19.5 M 17.4 M 17.5 M 15.8 M 15.8 M 12.4 M 10.3 M 8.09 M 8.09 M 5.95 M 5.95 M 5.95 M 5.95 M 5.91 M 5.73 M 5.73 M 5.1 M 4.05 M 3 M 2.7 M 2.77 M 3 M 2.64 M 77.5 M 80.6 M 79.1 M 76.2 M 70.2 M 71 M 76.2 M 68.6 M 56 M 60.6 M 68.6 M 51.7 M 42.9 M 45 M 51.7 M 43.9 M 38.4 M 39.1 M 39.9 M 23.4 M 16.4 M 16.4 M 23.4 M 16.4 M 16.4 M 16.4 M 16.4 M 16.4 M 16.4 M 16.4 M 16.4 M - 13.5 M 14.3 M 16.4 M

Net Income

 -3.79 M -2.71 M -2.7 M - -1.78 M -650 K -1.18 M - -2.37 M -1.3 M -1.76 M - -2.38 M -1.43 M -1.99 M -1.18 M -2.57 M -2.56 M -710 K 3.9 M -1.39 M -710 K -925 K -3.04 M -1.85 M -925 K -701 K -5.38 M -1.96 M -701 K -579 K -1.21 M -1.87 M -1.87 M -395 K -1.21 M -1.21 M -395 K -412 K -1.25 M -468 K -382 K -398 K - - -347 K -75.5 K - - - -119 K - - -232 K -130 K - -253 K -156 K

Revenue

 174 K 174 K 184 K - 84 K 145 K 151 K - 93.2 K 35 K 101 K - 99.7 K 30.6 K 13.9 K 692 K 204 K 192 K 296 K 251 K 36.4 K 37.5 K 10.3 K 97.5 K 59.9 K 62.1 K 22.2 K 337 K 140 K 172 K 24.6 K 51.1 K 29.3 K 12.6 K 9.22 K 32.2 K 6.22 K 15.2 K - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

 - - 2.72 K - - - 4.82 K - 12.7 K 2.96 K 15.8 K - 18.6 K 6.39 K 5.57 K 155 K 60 K 30.6 K 64.5 K 86.3 K 20.3 K 64.5 K 7.85 K 7.94 K 3.1 K 7.85 K 2.16 K 22.2 K 2.43 K 2.16 K 6.1 K - - - - - - - 14.4 K - 9.69 K 2.05 K - - - - 223 K - 175 K 165 K 145 K 518 K 229 K 143 K 211 K 576 K 153 K 212 K

Gross Profit

 174 K 174 K 181 K - 84 K 145 K 146 K - 80.4 K 32.1 K 85.7 K - 81.1 K 24.3 K 8.31 K 537 K 144 K 161 K 231 K 165 K 16.1 K 231 K 2.48 K 89.5 K 56.8 K 54.2 K 20.1 K 315 K 138 K 20.1 K 18.5 K 26.1 K 20.1 K 18.5 K 8.34 K -10.8 K -3.09 K 8.34 K -3.6 K -1.67 K -2.5 K -3.6 K - - - - 128 K - 76.2 K 88.3 K 104 K 371 K 265 K 1.72 K 51 K 301 K 174 K 75.8 K

Operating Income

 -3.75 M -2.75 M -2.69 M - -1.74 M -668 K -1.14 M - - - - - -2.42 M - - -4.38 M -2.57 M - - - - - - - - - - - - - -579 K - -866 K - -401 K - -264 K -275 K -412 K -1.37 M -511 K -459 K -398 K - -568 K - - -57.7 K -57.7 K - - - - - - - - -

Interest Expense

 - - -15.9 K - -41.4 K 15.3 K -45.9 K - - - - - - - - - - - - - - - - - - - - - - - - 4.89 K 1.58 K 1.95 K 1.36 K 1.12 K 1.05 K 1.36 K 77 31.5 K - 77 31.5 K 162 K 53.1 K 31.5 K 116 K 267 K 41.7 K 50.2 K 53.1 K 172 K 58.8 K 59.9 K 56.9 K 172 K 57.6 K 57.8 K

EBITDA

 - - -2.68 M - - - -1.11 M - - - 24.7 K - -2.42 M - 27.9 K -4.3 M -2.54 M 27.9 K 27.9 K 83.9 K 28.1 K 27.9 K 27.5 K 34.4 K 22.7 K 27.5 K 1.6 K 1.36 K 527 1.6 K -578 K 1.12 K -865 K 375 -400 K 464 -264 K -274 K -412 K -1.37 M -511 K -459 K -398 K - -568 K - - -57.7 K -57.7 K - - - - - 255 425 - 170

Operating Expenses

 3.92 M 2.93 M 2.87 M - 1.83 M 813 K 1.29 M - 2.46 M 1.34 M 1.85 M - 2.5 M 1.47 M 2.01 M 4.92 M 2.71 M 1.27 M 944 K 3.45 M 1.43 M 1.04 M 979 K 3.13 M 1.24 M 979 K 721 K 5.7 M 3.56 M 721 K 597 K 1.24 M 364 K 597 K 409 K 940 K 261 K 409 K 408 K 1.37 M 509 K 408 K 398 K 797 K 528 K 398 K 240 K 627 K 134 K 136 K 223 K 654 K 197 K 234 K 181 K 840 K 427 K 232 K

General and Administrative Expenses

 1.21 M 1.24 M 919 K - 1.25 M 567 K 711 K - 823 K 647 K 1.03 M - 1.75 M 1.2 M 1.55 M 4.1 M 2.26 M 1.09 M 752 K 194 K 55.4 K 76.5 K 74 K 207 K 81.9 K 74 K 72.9 K 183 K 64.8 K 72.9 K 46.2 K 112 K 41.6 K 35.8 K 23.4 K 10.7 K 2.05 K 2.91 K 4.04 K 19.8 K 8.74 K 4.04 K 5.62 K 8.22 K 7.04 K 5.62 K 4.18 K 6.76 K 410 1.87 K 1.13 K 2.28 K 628 524 1.42 K 4.28 K 2.27 K 592

All numbers in USD currency

The income statement is one of the three key financial reports of a company Lexaria Bioscience Corp. (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.